Recursion Pharmaceuticals (RXRX)
(Real Time Quote from BATS)
$5.55 USD
-0.25 (-4.31%)
Updated Aug 5, 2025 03:48 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/05/2025
Time: BMO |
9/2025 | $-0.32 | 1.03% |
Earnings Summary
For their last quarter, Recursion Pharmaceuticals (RXRX) reported earnings of -$0.41 per share, missing the Zacks Consensus Estimate of -$0.35 per share. This reflects a negative earnings surprise of 17.14%. Look out for RXRX's next earnings release expected on November 05, 2025. For the next earning release, we expect the company to report earnings of -$0.32 per share, reflecting a year-over-year increase of 12.5%.
Earnings History
Price & Consensus
Zacks News for RXRX
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
RXRX FAQs
Recursion Pharmaceuticals, Inc. (RXRX) has announced they will report their next quarter earnings on November 05, 2025. For the next earning release, we expect the company to report earnings of $-0.35 per share, reflecting a year-over-year increase of 12.50%.
Recursion Pharmaceuticals, Inc. has announced they will report their previous quarter earnings after the close of the market on November 05, 2025.
The Zacks Consensus Estimate for Recursion Pharmaceuticals, Inc. (RXRX) for the quarter ending in June 2025 is $-0.35 a share. We expect Recursion Pharmaceuticals, Inc. to miss by 1.03%.
In the earnings report for the quarter ending in June 2024, Recursion Pharmaceuticals, Inc. (RXRX) announced earnings of $-0.40 per share versus the Zacks Consensus Estimate of $-0.35 per share, representing a surprise of 14.29%.